Intervention

Fiasp

ClinicalTrials.gov intervention label

Clinical trials6

Recruiting0

Common conditions4

Lead sponsors shown5

Clinical trials

6 shown

A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 DiabetesNCT05199714 · 2022-02-21

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp StudyNCT05184868 · 2022-01-03

Fast Advanced Closed-Loop TherapyNCT04853030 · 2021-04-06

Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial PancreasNCT04163874 · 2020-02-14

AT247, NovoRapid® and Fiasp® in Glucose Clamp StudyNCT03959514 · 2019-04-12

Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop TherapyNCT03554486 · 2018-07-23

Common conditions

Diabetes Mellitus, Type 13 Type 1 Diabetes3 Hyperglycemia, Postprandial1 Type 1 Diabetes Mellitus1

Leading sponsors

Arecor Limited2 McGill University1 McGill University Health Centre/Research Institute of the McGill University Health Centre1 Stanford University1 University of Ljubljana, Faculty of Medicine1

Trial status mix

COMPLETED6

Phase mix

NA3

PHASE12

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.